Literature DB >> 31859176

Serum phosphate: Does it more closely reflect the true state of acromegaly?

Tao Xie1, Pei Tian1, Silin Wu1, Xiaobiao Zhang2, Tengfei Liu1, Ye Gu1, Chongjing Sun1, Fan Hu1.   

Abstract

An increased serum phosphate (P) level is common in acromegaly patients, however, the relationships among P, growth hormone (GH), insulin-like growth factor 1 (IGF-1) and disease status remain unknown. To reveal these relationships, we examined the association of P with comprehensive clinical data. We measured the serum P, calcium, GH, oral glucose tolerance test-GH (OGTT-GH), IGF-1, and insulin-like growth factor binding protein-3 (IGBP-3) levels in 103 acromegaly patients. SAGIT® was used to assess the disease status comprehensively. Spearman's rank correlation coefficient was obtained to evaluate the associations among the above parameters. Stepwise multiple linear regression analysis was performed to investigate factors independently associated factors with the SAGIT scores. The area under the receiver operating characteristic curve (AUCROC) was used to evaluate the efficacy of the percentage change in the serum phosphate level in predicting remission in patients with postoperatively discordant GH and IGF-1 levels. Hyperphosphatemia was found in 68.9% of patients at baseline. The serum P level was higher in the non-remission group, but no correlation was found between hyperphosphatemia and remission. We revealed a significant correlation between the P level and SAGIT® score in patients both preoperatively (r = 0.659, p = 0.000) and 1-year postoperatively without remission patients (r = 0.534, p = 0.027). All biochemical levels decreased significantly postoperatively, and the GH and OGTT-GH levels achieved early stability (1 month); however, the P, IGF-1 and IGBP-3 levels showed a gradual decline. A percentage change in P of -8.12% is recommended as a cut-off value for predicting remission in patients with postoperatively discordant GH and IGF-1 levels. As a metabolic product which affected by the GH/IGF-1 axis, serum P appears to more closely reflect the comprehensive disease status in acromegaly. When the GH and IGF-1 levels are discordant during follow-up, perioperative change in the P level may be a potential predictor of remission.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acromegaly; Growth hormone; Phosphate; Pituitary adenoma

Mesh:

Substances:

Year:  2019        PMID: 31859176     DOI: 10.1016/j.jocn.2019.11.012

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment.

Authors:  Alexandra A Povaliaeva; Viktor P Bogdanov; Artem Yu Zhukov; Ekaterina A Pigarova; Larisa K Dzeranova; Liudmila Ya Rozhinskaya; Galina A Mel'nichenko; Natalia G Mokrysheva
Journal:  Endocrine       Date:  2022-02-09       Impact factor: 3.633

Review 2.  Growth Hormone and IGF1 Actions in Kidney Development and Function.

Authors:  Evgenia Gurevich; Yael Segev; Daniel Landau
Journal:  Cells       Date:  2021-11-30       Impact factor: 6.600

3.  Renal effects of growth hormone in health and in kidney disease.

Authors:  Dieter Haffner; Andrea Grund; Maren Leifheit-Nestler
Journal:  Pediatr Nephrol       Date:  2021-06-18       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.